Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

The role of health-related economy is crucial due to the finite healthcare resources. Intravenous (i.v.) regimes Nordic FLOX and Nordic FLIRI, and the partly oral alternatives XELIRI and XELOX are four commonly used chemotherapies in the first-line treatment of advanced colorectal cancer (CRC) in the Scandinavian countries, all with different costs.
OriginalsprogEngelsk
TidsskriftActa Odontologica Scandinavica
Vol/bind51
Udgave nummer7
Sider (fra-til)840-8
Antal sider9
ISSN0001-6357
DOI
StatusUdgivet - sep. 2012
Eksternt udgivetJa

ID: 45707850